Los Alamos National Laboratory treatments.

These results were financed offshoots from a study to understand the interactions between buckyballs and biological membranes. Los Alamos National Laboratory. Proactive role by initiating a nanomaterial bioassessmnet program with the intent of its nanomaterial workers transferred safely and facilitates the discovery of high – function, to benefit low – bioimpact nanomaterials with potential national security missions In addition to Gao and Iyer, the LANL program includes Jennifer Hollingsworth, Yi Jiang Jian Song, Paul Welch, Hsing Lin Wang, Srinivas Iyer , and Gabriel Monta? treatments

Los Alamos National Laboratory researchers are trying to continue, the potential effects of exposure to nanomaterials in the same way that Los Alamos was a worldwide leader in understanding the effects of radiation during the Lab ‘s early history to understand. Los Alamos workers using nanomaterials continue to follow protocols the highest level of the highest level of protection from potential exposure.

Of H1N1 respiratory symptoms more reliable indicator H1N1, non fever aloneRecent research indicates that people with a mild H1N1 infected unidentified with a standard diagnostic criteria for, according to one study in the August issue of the American Journal of Infection Control, the official publication of of Association for Professionals into infection Control and Epidemiology, the study come to the conclusion in that coughs or other respiratory symptoms be more accurate determination of influenza infection than the presence of temperature.

Safe Harbor StatementThis News Release is contains forward-looking statements that include risk and insecurities that cause that our actual results and experience gained of from the expected outcomes and expectations reflected in such forward-looking statements expressed. These forward looking statements include, without limitation, statements concerning the of action of CM -AT, their potential advantages, its potential for application in the treatment of autism, and the time of , progress and anticipated outcomes of clinical developing and regulatory process reference CM -AT. Amongst others risk on our current knowledge beliefs and expectations regarding to such future outcomes , and is subject to known and unknown risks and uncertainties, actual future experience and results could result from the statements made. In that cause such a material difference includes, among others, risks that will results of clinical trials does not support of our claims or convictions on the effectiveness of the CM AT, out our ability to adjust our development of out of CM AT, regulatory risks As be financed, and our dependence on the Third researcher and other collaborators. We are disclaim any obligation statements except as statements except as required by law.